The biotechnology company provides an update on the progress of its core programs focused on the SIRT6-centenarian gene and its potential to slow aging and delay the onset of age-related diseases.
The biotechnology company has signed a master service agreement with a research partner to accelerate its pre-IND gene therapy programs.
The biotechnology company has announced the details of its upcoming Annual General Meeting.
The biotechnology company announces an important step in the protection of its SIRT6 intellectual property, with the Japanese Patent Office advancing the application to the national examination phase.
The biotechnology company has disclosed a change in director shareholding.
The biotechnology company has raised £500,000 through a share subscription and is advancing a proof-of-concept trial evaluating the safety and efficacy of its therapeutic candidate in aged dogs.
The pre-clinical biotech firm reported increased losses and significantly reduced cash reserves, raising concerns about its financial sustainability despite progress in research programs.
The biotechnology company has signed an agreement with an AI firm to boost its gene therapy research capabilities.
The biotechnology company is launching a new ophthalmology development program, leveraging its proprietary Centenarian SIRT6 technology to target ocular diseases.
The biotechnology company has announced a director has increased their shareholding in the business.